References

  • Fay A, Abinun M. Current management of hereditary angio-oedema (C’1 esterase inhibitor deficiency). J Clin Pathol. 2002;55(4):266-270.
  • Agostoni A, Aygören-Pürsün E, Binkley KE, et al. Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond. J Allergy Clin Immunol. 2004;114(3 suppl):S51-S131.
  • Frank MM. Hereditary angioedema. J Allergy Clin Immunol. 2008;121(2 suppl):S398-S401.
  • Gompels MM, Lock RJ, Abinun M, et al. C1 inhibitor deficiency: consensus document. Clin Exp Immunol. 2005;139(3):379-394.
  • Bowen T, Brosz J, Brosz K, et al. Management of hereditary angioedema : 2010 Canadian approach. Ann Allergy Asthma Immunol. 2010;6:20 (suppl 1): doi:10.1186/1710-1492-6-20.
  • Zuraw B. Clinical practice. Hereditary angioedema. N Engl J Med. 2008;359(10):1027-1036.
  • Heymann WR, Rossy K. Angioedema, hereditary. eMedicine from WebMD. http://www.emedicine.com/derm/topic24.htm. Accessed January 4, 2009.
  • Nzeako UC, Frigas E, Tremaine WJ. Hereditary angioedema: a broad review for clinicians. Arch Intern Med. 2001;161(20):2417-2429.
  • Sheffer AL. Hereditary angioedema: optimal therapy. J Allergy Clin Immunol. 2007;120(4):756-757.
  • Weiler CR, van Dellen RG. Genetic test indications and interpretations in patients with hereditary angioedema. Mayo Clin Proc. 2006;81(7):958-972.
  • Schousboe I. Binding of activated Factor XII to endothelial cells affects its inactivation by the C1-esterase inhibitor. Eur J Biochem. 2003;270(1):111-118.
  • Craig TJ, Levy RJ, Wasserman RL, et al. Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary angioedema attacks. J Allergy Clin Immunol. 2009;124(4):801-808.
  • Reshef A, Leibovich I, Goren A. Hereditary angioedema: new hopes for an orphan disease. Isr Med Assoc J. 2008;10(12):850-855.
  • Bygum A, Andersen, KE, Mikkelsen CS. Self-administration of intravenous C1-inhibitor therapy for hereditary angioedema and associated quality of life benefits. Eur J Dermatol. 2009;19(2):147-151.
  • Levy JH, Freiberger DJ, Roback J. Hereditary angioedema: current and emerging treatment options. Anesth Analg. 2010;110(5):1271-1280.
  • Zuraw B, Yasothan U, Kirkpatrick P. Ecallantide. Nat Rev Drug Discov. 2010;9(3):189-190.
  • Bork K, Barnstedt SE. Treatment of 193 episodes of laryngeal edema with C1 inhibitor concentrate in patients with hereditary angioedema. Arch Intern Med. 2001;161(5):714-718.
  • Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. Critical role of kallikrein in hereditary angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor. J Allergy Clin Immunol. 2007;120(2):416-422.
  • Bowen T, Cicardi M, Bork K, et al. Hereditary angioedema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the diagnosis, therapy, and management of hereditary angioedema. Ann Allergy Astma Immunol. 2008;100(1) (suppl2):S30-S40.